Impact of Replacement Therapy on the Evolution of HIV Infection in Hemophiliacs

• References

• 1 Melbye M, Madhok R, Sarin PS, Lowe GDO, Goedert JJ, Froebel KS, Biggar RJ, Senbjerg S, Forbes CD, Gallo RC, Ebbesen P. HTLV-III sero-positivity in European haemophiliacs exposed to factor VIII concentrates imported from the USA. Lancet 1984; ii: 1444-6
• 2 Ledermann MM, Ratnoff OD, Evatt BL, Mc Dougal JS. Acquisition of antibody to lymphadenopathy-associated virus in patients with classic hemophilia (factor VIII deficiency). Ann Intern Med 1985; 102: 753-7
• 3 Hattori T, Ikematsu S, Chosa T, Yanamoto S, Matsuoka M, Fukutake K, Robert-Guroff M, Takatsuki K. Anti-HTLV III and Anti-HTLV-I antibodies and T-cell subsets in hemophiliacs living in HTLV-I endemic and nonendemic areas of Japan. Acta Haematol (Basel) 1987; 77: 25-9
• 4 Suomela H. Inactivation of viruses in blood and plasma products. Transfusion Medicine Reviews 1993; 1: 42-57
• 5 Evatt BL, Gomperts ED, Mc Dougal JS, Ramsey RB. Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 1985; 312: 483-6
• 6 Eyster ME, Goedert JJ, Samgadharan MG, Weiss SH, Gallo RC, Blattner WA. Development and early natural history of HTLV-III antibodies in persons with hemophilia. J Am Med Assoc 1985; 253: 2219-23
• 7 Bemtorp E, Hansson BG, Böttiger B, Jarevi G, Wedbäck A, Nordenfelt E, Nillson IM. HIV seroconversion in Swedish haemophiliacs: Relation to type and dosage of factor concentrate. Eur J Haematol 1987; 38: 256-60
• 8 Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White II GC, Drummond JE, Vaidya K, Mann DL, Eyster E, Ragni MV, Lederman MM, Cohen AR, Bray GL, Rosenberg PS, Friedman RM, Hilgartner MW, Blattner WA, Kroner B, Gail MH. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321: 1141-8
• 9 Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol 1988; 40: 205-14
• 10 Nilsson IM, Berntorp E. Clinical efficacy of clotting factor concentrates – survival, recovery and haemostatic capacity. In: Coagulation and blood transfusion. Smit Sibinga CTh, Das PC, Mannucci PM. eds Dordrecht: Kluwer Academic Publishers; 1991: 193-206
• 11 Bemtorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993; 70: 768-73
• 12 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540-5
• 13 Kim HC, Mc Millan CW, White GC, Bergman GF, Saidi P. Clinical experience of a new monoclonal antibody purified factor IX: Half-life, recovery, and safety in patients with hemophilia B. Semin Hematol 1990; 27 Suppl (Suppl. 02) 30-5
• 14 Watson HG, Ludlam CA. Immunological abnormalities in haemophiliacs. Blood Reviews 1992; 6: 26-33
• 15 Eibl MM, Ahmad R, Wolf HM, Linnau Y, Gotz E, Mannhalter JW. A component of factor VIII preparations which can be separated from factor VIII activity downmodulates human monocyte functions. Blood 1987; 69: 1153-60
• 16 Pasi KJ, Hill FGH. In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purity. Br J Haematol 1990; 76: 88-93
• 17 Lederman MM, Saunders C, Toosi Z, Lemon N, Everson B, Ratnoff OD. Anti-haemophilic factor (factor VIII) preparations inhibit lymphocyte proliferation and production of interleukin-2. J Lab Clin Med 1986; 107: 471-8
• 18 Hay CRM, Mc Evoy P. Purity of factor VIII concentrates. Lancet 1992; 339: 1613
• 19 Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immuno-suppression in haemophiliacs. Br J Haematol 1989; 71: 387-91
• 20 Hay CRM, Mc Evoy P, Duggan-Keen M. Inhibition of lymphocyte II.2-re-ceptor expression by factor VIII concentrate: a possible cause of immuno-suppression in haemophiliacs. Br J Haematol 1990; 75: 278-81
• 21 Vermot-Desroches C, Rigal D, Blourde C, Bernaud J. Immunosuppressive property of a very high purity antihaemophilic preparation: a low molecular weight component inhibits an early step of PHA induced cell activation. Br J Haematol 1992; 80: 370-7
• 22 Madhok R, Gracie A, Lowe GDO, Burnett A, Froebel K, Follet E, Forbes CD. Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Br Med J 1986; 293: 978-80
• 23 Aledort LM. Blood products and immune changes: Impacts without HIV infection. Semin Hematol 1988; 25: 14-20
• 24 Cuthbert RJG, Ludlam CA, Steel CM, Beatson D, Peutherer JF. Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy. Br J Haematol 1992; 80: 364-9
• 25 Sullivan JL, Brewster FE, Brettler DB, Forsberg AD, Cheesman SH, Byron KS, Levine PH. Hemophilic immunodeficiency: Influence of exposure to factor VIII concentrate. LAV/HTLV-III and herpes viruses. J Pediatr 1986; 108: 504-10
• 26 Wolf HM, Pum M, Jáger R, István L, Mannhalter JW, Eibl MM. Cellular and humoral immune responses in haemophiliacs after vaccination against tick-borne encephalitis. Br J Haematol 1992; 82: 374-83
• 27 Madhok R, Gracie JA, Smith J, Lowe GDO, Forbes CD. Capacity to produce interleukin 2 is impaired in haemophilia in the absence and presence of HIV 1 infection. Br J Haematol 1990; 76: 70-4
• 28 Madhok R, Cruickshank A, Gracie AJ, Shenkin A, Lowe GDO. Increased interleukin 6 concentrations in the absence and presence of HIV-1 infection in haemophilia. J Clin Pathol 1992; 45: 766-9
• 29 Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167: 322-44
• 30 Evans JA, Pasi KJ, Williams MD, Hill FGH. Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y). Br J Haematol 1991; 79: 457-61
• 31 Funk M, Ebener U, Kreuz W, Ehrenforth S. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates. Lancet 1993; 342: 933-4
• 32 Fukutake K, Hada M, Ikematsu S, Fujimaki M, Hanabusa S, Inagaki M, Mimaya Jun-ich, Shirahata A. Multicenter study on the influence of long-term continuous use of ultrapurified factor VIII preparation on the immunological status of HIV-infected and non-infected hemophilia A patients. XIX international congress of The World Federation of Hemophilia. Washington DC: 1990. abstract no. 124
• 33 Mannucci PM, Abildgaard CF, Aledort M, Lucher JM, Brettler DB, Bogdanoff D, Schwartz RS, Hurst D. and the Kogenate Study Group Immune function over 3.5 years in HIV positive and HIV negative hemophilia patients receiving recombinant FVIII (Kogenate). Thromb Haemost 1993; 69 (06) 1205 (abstract no. 2362)
• 34 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32
• 35 Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIII :C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 1859-63
• 36 Gomperts E, Addiego J, Gill J. What is the impact of monoclonal Ab purified, plasma derived FVIII on immune function in hemophilia A patients?. Blood 1989; 75 Suppl (01) 39a (abstract)
• 37 de Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate. Blood 1991; 78: 1919-22
• 38 Mannucci PM, Gringeri A, de Biasi R, Baudo F, Morfini M, Ciavarella N. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. Thromb Haemost 1992; 67: 310-3
• 39 Mannucci PM, Gringeri A, Cattaneo M. High-purity factor VIII concentrates produced without using monoclonal antibodies. Res Clin Lab 1990; 20: 227-38
• 40 Seremetis SV, Aledort LM, Bergman GE, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lau T-S, Lusher J, Rickies F. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet 1993; 342: 700-3
• 41 Eyster ME, Gail MH, Ballard JO, Al-Mondhiry H, Goedert JJ. Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Int Med 1987; 107: 1-6
• 42 Goldsmith JM, Deutsche J, Tang M, Green D. CD4 Cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates. Thromb Haemost 1991; 66: 415-9
• 43 Hilgartner MW, Buckley JD, Operskalski EA, Pike MC, Mosley JW. Purity of factor VIII concentrates and serial CD4 counts. Lancet 1993; 341: 1373-4
• 44 Jason J, Lui K-J, Ragni MV, Hessol NA, Darrow WW. Risk of developing AIDS in HIV-infected cohorts of hemophilic and homosexual men. JAMA 1989; 261: 725-7
• 45 Lee CA, Phillips AN, Elford J, Miller EJ, Bofill M, Griffiths PD, Kernoff PBA. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Br J Haematol 1989; 73: 228-34
• 46 Giesecke J, Scalia-Tomba G, Berglund O, Berntorp E, Schulman S, Stigendal L. Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus. Br Med J 1988; 297: 99-102
• 47 Darby SC, Rizza CR, Doll R, Spooner RJD, Stratton R, Thaker B. Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the United Kingdom: Report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J 1989; 298: 1064-8
• 48 Schinaia N, Ghirardini A, Chiarotti F, Gringeri A, Mannucci PM. and the Italian Group. Progression to AIDS among Italian HIV-positive haemophiliacs. AIDS 1991; 5: 385-91
• 49 Simmonds P, Beatson D, Cuthbert RJG, Watson H, Reynolds B, Peutherer JF, Parry JV, Ludlam CA, Steel CM. Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet 1991; 338: 1159-6